Stock Scorecard
Stock Summary for ImmunityBio Inc (IBRX) - $5.52 as of 1/16/2026 10:00:40 PM EST
Total Score
6 out of 30
Safety Score
23 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for IBRX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for IBRX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for IBRX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for IBRX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for IBRX (23 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 7 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for IBRX
Financial Details for IBRX
Company Overview |
|
|---|---|
| Ticker | IBRX |
| Company Name | ImmunityBio Inc |
| Country | N/A |
| Description | ImmunityBio, Inc. is an advanced immunotherapy company focused on pioneering treatments that leverage the unique capabilities of memory T-cells to combat a variety of cancers. Its proprietary cancer vaccine signifies a transformative approach in oncology, emphasizing greater therapeutic efficacy with reduced reliance on traditional high-dose chemotherapy. With a robust biotechnology platform, ImmunityBio is set to redefine cancer treatment paradigms and significantly improve patient outcomes, positioning itself as a frontrunner in the evolving field of cancer therapeutics. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/2/2026 |
Stock Price History |
|
| Last Day Price | 5.52 |
| Price 4 Years Ago | 5.07 |
| Last Day Price Updated | 1/16/2026 10:00:40 PM EST |
| Last Day Volume | 182,353,701 |
| Average Daily Volume | 22,422,638 |
| 52-Week High | 4.27 |
| 52-Week Low | 1.83 |
| Last Price to 52 Week Low | 201.64% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 58.69 |
| Sector PE | 54.65 |
| 5-Year Average PE | -5.31 |
| Free Cash Flow Ratio | 92.00 |
| Industry Free Cash Flow Ratio | 12.67 |
| Sector Free Cash Flow Ratio | 28.78 |
| Current Ratio Most Recent Quarter | 5.77 |
| Total Cash Per Share | 0.06 |
| Book Value Per Share Most Recent Quarter | -0.53 |
| Price to Book Ratio | 0.00 |
| Industry Price to Book Ratio | 10.48 |
| Sector Price to Book Ratio | 43.34 |
| Price to Sales Ratio Twelve Trailing Months | 24.10 |
| Industry Price to Sales Ratio Twelve Trailing Months | 35.65 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.82 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 984,965,000 |
| Market Capitalization | 5,437,006,800 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 29.09% |
| Reported EPS 12 Trailing Months | -0.41 |
| Reported EPS Past Year | -0.32 |
| Reported EPS Prior Year | -0.60 |
| Net Income Twelve Trailing Months | -348,616,000 |
| Net Income Past Year | -413,564,000 |
| Net Income Prior Year | -583,196,000 |
| Quarterly Revenue Growth YOY | 425.10% |
| 5-Year Revenue Growth | 221.39% |
| Operating Margin Twelve Trailing Months | -173.50% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 60,241,000 |
| Total Cash Past Year | 143,428,000 |
| Total Cash Prior Year | 265,453,000 |
| Net Cash Position Most Recent Quarter | -440,563,000 |
| Net Cash Position Past Year | -318,449,000 |
| Long Term Debt Past Year | 461,877,000 |
| Long Term Debt Prior Year | 681,537,000 |
| Total Debt Most Recent Quarter | 500,804,000 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | -489,098,000 |
| Total Stockholder Equity Prior Year | -586,987,000 |
| Total Stockholder Equity Most Recent Quarter | -569,819,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -324,756,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.33 |
| Free Cash Flow Past Year | -398,124,000 |
| Free Cash Flow Prior Year | -397,341,000 |
Options |
|
| Put/Call Ratio | 0.06 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.32 |
| MACD Signal | 0.09 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | -0.04 |
| RSI | 0.00 |
| 50-Day SMA | 2.64 |
| 150-Day SMA | 3.47 |
| 200-Day SMA | 3.76 |
System |
|
| Modified | 1/15/2026 10:39:21 PM EST |